Skip to main content

Moore Paul Andrew's Form 4 filing

Zymeworks Inc. (ZYME) · filed Jan 6, 2025

Accession no.
0000950170-25-002501
Filed
Jan 6, 2025
Trade date
Jan 6, 2025
Filing delay
Same day
Rule 10b5-1 plan
Not checked

This filing lists 4 non-derivative transactions and 2 derivative transactions. Open-market sales total $316.3K. It was filed on the trade date.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Moore Paul AndrewCIK 0001938192Officer (Chief Scientific Officer)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Jan 6, 2025Common StockMOption exerciseAcquired+17,166$0.00$024,533Direct
Jan 6, 2025Common StockSSaleDisposed−9,792$14.92−$146,096.6414,741Direct
Jan 6, 2025Common StockMOption exerciseAcquired+20,000$0.00$034,741Direct
Jan 6, 2025Common StockSSaleDisposed−11,408$14.92−$170,207.3623,333Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Jan 6, 2025Common StockMOption exerciseDisposed−17,166$0.00$017,168Direct
Jan 6, 2025Common StockMOption exerciseDisposed−20,000$0.00$040,000Direct

Footnotes

Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.

Read the original on SEC EDGAR (opens in a new tab)